1. Apoptosis Metabolic Enzyme/Protease NF-κB
  2. Apoptosis Endogenous Metabolite NF-κB
  3. Ursonic acid

Ursonic acid  (Synonyms: 熊果酮酸; 3-Ketoursolic acid)

目录号: HY-N1486 纯度: 98.15%
COA 产品使用指南

Ursonic acid 是一种天然的三萜酸,具有口服活性。Ursolic acid 可以通过多种信号通路诱发人类癌症细胞的细胞凋亡。Ursolic acid 具有抗炎和抗癌活性。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Ursonic acid Chemical Structure

Ursonic acid Chemical Structure

CAS No. : 6246-46-4

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥440
In-stock
5 mg ¥400
In-stock
10 mg ¥500
In-stock
25 mg ¥700
In-stock
50 mg ¥890
In-stock
100 mg ¥1350
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 1 篇科研文献

查看 NF-κB 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Ursolic acid is a naturally occurring triterpenoid that has orally active. Ursolic acid induces the apoptosis of human cancer cells through multiple signaling pathways. Ursolic acid has anti-inflammatory and anticarcinogenic activity[1][2].

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
> 50 μM
Compound: 7a
Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay
Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay
[PMID: 31677446]
A549 IC50
15 μM
Compound: 2
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
[PMID: 26854375]
A549 GI50
57 μM
Compound: 16
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 32345458]
ASPC1 IC50
24.5 μM
Compound: 4
Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay
Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay
[PMID: 22959527]
BJ IC50
> 50 μM
Compound: 7a
Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay
Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay
[PMID: 31677446]
CCRF-CEM IC50
10.4 μM
Compound: 7a
Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay
Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay
[PMID: 31677446]
HCT-116 IC50
> 50 μM
Compound: 7a
Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay
Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay
[PMID: 31677446]
HCT-116 IC50
2.3 μM
Compound: 2
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
[PMID: 26854375]
HCT-116 IC50
49.7 μM
Compound: 7a
Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
[PMID: 31677446]
HCT-116 GI50
5.3 μM
Compound: 16
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 32345458]
HeLa IC50
> 40 μM
Compound: 2
Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay
Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay
[PMID: 28733083]
HepG2 IC50
> 100 μM
Compound: 2
Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
[PMID: 25537271]
HepG2 CC50
> 400 μM
Compound: 4a
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 29326018]
HL-60 IC50
> 40 μM
Compound: 2
Growth inhibition of human HL60 cells after 48 hrs by MTT assay
Growth inhibition of human HL60 cells after 48 hrs by MTT assay
[PMID: 28073673]
K562 IC50
> 50 μM
Compound: 7a
Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay
Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay
[PMID: 31677446]
MCF7 GI50
12 μM
Compound: 16
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 32345458]
MCF7 IC50
56 μM
Compound: 2
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 26854375]
MDA-MB-231 IC50
> 40 μM
Compound: 2
Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay
[PMID: 28733083]
MRC5 IC50
> 50 μM
Compound: 7a
Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay
Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay
[PMID: 31677446]
NTUB1 IC50
21.44 μM
Compound: 18
Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay
Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay
[PMID: 19758808]
RAW264.7 IC50
4.94 μM
Compound: 2
Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess assay
Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess assay
[PMID: 28427811]
SMMC-7721 IC50
> 40 μM
Compound: 2
Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay
Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay
[PMID: 28733083]
THP-1 IC50
13 μM
Compound: 2
Cytotoxicity against human THP1 cells after 48 hrs by MTT assay
Cytotoxicity against human THP1 cells after 48 hrs by MTT assay
[PMID: 26854375]
U2OS IC50
> 50 μM
Compound: 7a
Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay
Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay
[PMID: 31677446]
Vero CC50
> 400 μM
Compound: 4a
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
[PMID: 29326018]
Vero IC50
2.5 μg/mL
Compound: 5, ursonic acid
Antiviral activity against HSV1 MacIntyre replication in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against HSV1 MacIntyre replication in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
[PMID: 2828553]
Vero IC50
8 μg/mL
Compound: 5, ursonic acid
Antiviral activity against HSV2 MS replication infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against HSV2 MS replication infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
[PMID: 2828553]
体外研究
(In Vitro)

Ursolic acid (12.5-50 μM, 48 h) 通过抑制 AKT/NF-κB 信号通路以剂量依赖性方式诱导 T24 人膀胱癌细胞凋亡[1]
Ursolic acid (50 μM, 2-4 h) 可增加 B16F-10 黑色素瘤细胞中 p53 和 caspase-3 的表达并降低 bcl-2 基因表达[2]
Ursolic acid (10-50 μM, 48 h) 抑制 B16F-10 黑色素瘤细胞中 TNF-α、IL-1β、IL-6 和 GM-CSF 的产生[2]
Ursolic acid (50 μM, 2 h) 抑制 B16F-10 黑色素瘤细胞中的 NF-κB 亚基 (p65、p50 和 c-Rel) 以及 c-fos、ATF-2 和 CREB-1 的核转位[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: T24 human bladder cancer cells
Concentration: 12.5-50 μM
Incubation Time: 48 h
Result: Inhibited cell proliferation in a dose-dependent manner.

Western Blot Analysis[1]

Cell Line: T24 human bladder cancer cells
Concentration: 12.5-50 μM
Incubation Time: 48 h
Result: Inhibited the anti-apoptotic signaling (pAkt1, pIκBα, NF-κBp65 and Bcl-2).
Activated pro-apoptotic signaling (caspase-3).
体内研究
(In Vivo)

Ursolic acid (5-20 mg/kg,口服,每天两次,持续 30 天) 可保护成年雄性白化大鼠免受乙醇介导的实验性肝损伤[3]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adult male albino rats[3]
Dosage: 5-20 mg/kg
Administration: p.o., twice a day, 30 days
Result: Increased weight gain and food intake.
Decreased AST and ALT activities and total and indirect bilirubin levels.
Increased direct bilirubin and levels of non-enzymic antioxidants (GSH, ascorbic acid and a-tocopherol).
Decreased lipid peroxidation.
分子量

454.68

Formula

C30H46O3

CAS 号
性状

固体

颜色

White to off-white

中文名称

熊果酮酸

结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 50 mg/mL (109.97 mM; 超声助溶 (<80°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1993 mL 10.9967 mL 21.9935 mL
5 mM 0.4399 mL 2.1993 mL 4.3987 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.50 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (5.50 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液,此方案实验周期在半个月以上的动物实验酌情使用。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 98.15%

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1993 mL 10.9967 mL 21.9935 mL 54.9837 mL
5 mM 0.4399 mL 2.1993 mL 4.3987 mL 10.9967 mL
10 mM 0.2199 mL 1.0997 mL 2.1993 mL 5.4984 mL
15 mM 0.1466 mL 0.7331 mL 1.4662 mL 3.6656 mL
20 mM 0.1100 mL 0.5498 mL 1.0997 mL 2.7492 mL
25 mM 0.0880 mL 0.4399 mL 0.8797 mL 2.1993 mL
30 mM 0.0733 mL 0.3666 mL 0.7331 mL 1.8328 mL
40 mM 0.0550 mL 0.2749 mL 0.5498 mL 1.3746 mL
50 mM 0.0440 mL 0.2199 mL 0.4399 mL 1.0997 mL
60 mM 0.0367 mL 0.1833 mL 0.3666 mL 0.9164 mL
80 mM 0.0275 mL 0.1375 mL 0.2749 mL 0.6873 mL
100 mM 0.0220 mL 0.1100 mL 0.2199 mL 0.5498 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Ursonic acid
目录号:
HY-N1486
需求量: